FOLD
Amicus Therapeutics Inc

6,439
Mkt Cap
$4.42B
Volume
10.55M
52W High
$14.36
52W Low
$5.51
PE Ratio
-319.46
FOLD Fundamentals
Price
$14.28
Prev Close
$14.28
Open
$14.28
50D MA
$10.96
Beta
0.84
Avg. Volume
16.2M
EPS (Annual)
-$0.1843
P/B
19.12
Rev/Employee
$1.06M
Loading...
Loading...
News
all
press releases
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations
AMRN jumps 17% after Q4 and FY2025 preliminary sales beat expectations. The release also reflected positive Q4 cash flow and progress on cost cuts.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress
Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.
Zacks·2d ago
News Placeholder
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their...
PR Newswire·3d ago
News Placeholder
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.
Zacks·3d ago
News Placeholder
KRYS Stock Surges 57% in a Year: More Upside Potential in 2026?
Shares of Krystal Biotech soar 57% in a year as strong Vyjuvek uptake and steady pipeline progress continue to push the stock higher.
Zacks·3d ago
News Placeholder
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study
Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.
Zacks·3d ago
News Placeholder
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.
Zacks·4d ago
News Placeholder
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?
CELC shares surge as NDA filing and strong phase III data boost optimism around gedatolisib's potential.
Zacks·5d ago
News Placeholder
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?
Galafold drives over 80% of Amicus product revenues, with $371.5M in the first nine months of 2025 sales as investors await Q4 sales performance.
Zacks·5d ago
News Placeholder
Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their...
PR Newswire·5d ago
<
1
2
...
>

Latest FOLD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.